Adverse Events Seen With JAK Inhibitors for Myelofibrosis

Opinion
Video

The JAK inhibitors approved for myelofibrosis have common side effects of cytopenias and gastrointestinal issues, with additional risks of weight gain and cardiac effects and diarrhea; momelotinib and pacritinib show improved tolerability compared to earlier JAK inhibitors.

Recent Videos
Image of a woman in front of a blue Oncology Nursing News-branded backdrop.
Smiling woman in front of a blue video call background with logos that say "All in Against Cancer" and "Ochsner Health" above her
Related Content